• Anna Tirilomi, Petros Tirilomis, Omar Elakad, Sha Yao, Marc Hinterthaner, Bernhard C Danner, Philipp Ströbel, Theodor Tirilomis, Hanibal Bohnenberger, and Alexander von Hammerstein-Equord.
• Department of Cardio-Thoracic and Vascular Surgery, University Medical Center, Göttingen, Germany.
• Medicine (Baltimore). 2024 Oct 4; 103 (40): e39911e39911.

AbstractMalignant tumors of the lung are the leading cancers worldwide. Prognostic biomarkers continue to be investigated for the detection and stratification of lung cancer for clinical use. In breast cancer cells and in lymphomas, the overexpression of galectin-7 led to increased metastasis. In lung cancer, squamous cell carcinoma, galectin-7 was also identified as a factor promoting metastasis. In this study, we investigated the expression of galectin-7 in relation to clinicopathological features and overall survival in patients with different types of lung cancer. By immunohistochemistry, expression of galectin-7 was analyzed in 308 cases of lung cancer; 108 cases of adenocarcinoma, 193 cases of squamous cell lung carcinoma and 7 cases of small cell lung cancer (SCLC) and correlated with clinicopathological characteristics as well as patients' overall survival. Immunohistochemical detection of galectin-7 expression was most evident in squamous cell lung carcinoma (36.27%), followed by adenocarcinoma (5.55%). Negative expression of galectin-7 was found in all patients with SCLC. No significant correlation was found in patients with squamous cell lung carcinoma. Within the adenocarcinoma and squamous cell lung carcinoma subgroups, there were statistically significant correlations between the expression of galectin-7 and some clinicopathologic features of the patients. In our study, we were able to show that galectin-7 could serve as a new prognostic biomarker and is also a potential new drug target in non-small cell lung cancer.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

31 keywords...

hide…